- ￥366 - 4660
- MedChemExpress(MCE)
- 美国
- HY-X0150
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
2247481-21-4
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1222.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥366.0 |
| 规格： | 5 mg | 产品价格： | ￥1100.0 |
| 规格： | 10 mg | 产品价格： | ￥1760.0 |
| 规格： | 25 mg | 产品价格： | ￥3340.0 |
| 规格： | 50 mg | 产品价格： | ￥4660.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
JSH-150
CAS No. : 2247481-21-4
MCE 国际站：JSH-150
产品活性：JSH-150 是一种高效的选择性 CDK9 抑制剂， IC50 为 1 nM。
研究领域：Cell Cycle/DNA Damage
作用靶点：CDK
In Vitro: The antiproliferative effect of JSH-150 is examined ton a panel of established cancer cell lines. JSH-150 exhibits potent antiproliferative activities in solid tumor cell lines such as A375 (melanoma), A431 (squamous), BE(2)M17 (neuroblastoma), GIST-T1 (GIST) and COLO205 (colon cancer) with GI50 values from 0.002 to 0.044 µM. In the leukemia cell lines including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and B cell lymphoma cell lines, JSH-150 also displays strong growth inhibition efficacies with GI50s ranging from single to double digit nM. In addition, JSH-150 is much less sensitive in normal CHO cells (GI50: 1.1 µM) compared with the cancer cell lines.
In Vivo: Treatment of JSH-150 at all dosages, i.e., 10, 20 and 30 mg/kg/day, can almost completely suppress the tumor progression in the first two weeks and does not affect the animal’s weight indicating that there is no general cytotoxicity at these doses. After stopping the treatment of JSH-150, the tumors of the animals treated with 10 mpk drug dosage start to grow again. However, this tumor recurrence is not observed in the 20 and 30 mpk dosage groups during the following week after administration of JSH-150 is stopped and p values are quantified on the 21st day, which are 0.042, 0.0035 and 0.0028, respectively. The PK properties of JSH-150 are evaluated in different species including mice, Sprague-Dawley rats and beagle dogs through intravenous injection and oral administration. JSH-150 is absorbed rapidly in dogs and mice (Tmax=1.33 h and 2.00 h respectively) but slowly in rats (Tmax=3.33 h). JSH-150 also displays different half-lives in three different species via oral administration (T1/2=1.55 h in mice, 3.37 h in rats and 20.37 h in dogs), which indicates that it is metabolized very slowly in dogs compared with mice and rats. In addition, JSH-150 exhibits acceptable bioavailability in mice, rats and dogs (F=45.01%, 45.10% and 39.15%, respectively). The PK properties indicated that JSH-150 is suitable for oral administration.
相关产品：Covalent Screening Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Kinase Inhibitor Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Covalent Screening Library | Anti-Breast Cancer Compound Library | Anti-Blood Cancer Compound Library | Targeted Diversity Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Highly Selective Inhibitors Library | Serine/Threonine Kinase Inhibitor Library | Palbociclib | Abemaciclib | Ro-3306 | Ribociclib | Dinaciclib | GSK3326595 | THZ1 | Flavopiridol | SR-4835 | (R)-Roscovitine | THZ531 | AZD4573 | SY-5609 | Kenpaullone | Wogonin | SNS-032 | GSK 3 Inhibitor IX | Cirtuvivint | NVP-2 | Toyocamycin | Fadraciclib | Simurosertib | AT7519 | OTS964 hydrochloride | JNJ-7706621 | KB-0742 dihydrochloride | BSJ-4-116
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验运动的确能降低死亡风险！但每周运动多久效果最佳？哈佛大学的最新研究给出答案……
研究，发现每周 150～300 分钟的剧烈运动，或是每周 300～600 分钟的中等强度运动，或两者的等效组合，与较低死亡率存在最大的相关性。 这一运动量是指南推荐最低运动量的 2～4 倍，每周 150～300 分钟的剧烈运动可降低死亡风险 21～23%，每周 300～600 分钟的中等强度运动可降低死亡风险 26-31%。 图片来源：Circulation 研究内容 研究人员分析了从两项大型前瞻性研究中收集的超过 100,000 名成年人的死亡率数据和医疗记录，参与者平均年龄为 66
外泌体（Exosomes）是细胞分泌到胞外的一种囊泡，大小为 30-150 nm，携带了各种核酸、蛋白质和脂类等物质，可以在不同细胞间进行传递和交流，从而影响受体细胞的生物学功能。 外泌体在大小和功能上与合成的纳米颗粒类似，但作为天然内源性载体，具有免疫原性低、毒性低、稳定性高、渗透性好等优势，故可能成为更有应用前景的药物递送载体。目前，外泌体已经成功运载基因类药物、抗癌药物和抗炎症药物等其他类型药物。 近年来，外泌体作为基因载体引起了基因治疗研究者的广泛关注。与传统的病毒或非
每天快走 11 分钟，即可降低死亡风险！剑桥大学研究揭示：简单运动也能带来健康益处
心血管疾病是全球的主要死因。2019 年，共有 1790 万人死于心血管疾病，占全球死亡总数的 31%。在心血管死亡事件中，85% 人群死于心脏病和中风。据多项研究表明，身体活动，尤其是中等强度运动，可降低心血管疾病和癌症的患病风险。英国国家医疗服务体系 NHS 曾建议，成年人每周应进行至少 150 分钟的中强度活动或 75 分钟的高强度活动。近日，有新研究表明，如果你坚持不了那么久，适度的中度运动也可达到保健预防的效果。 2023 年 2 月 28 日，剑桥大学临床医学院在
技术资料暂无技术资料 索取技术资料
